Efficacy and safety analysis of aripiprazole combined with magnesium valproate in treating depressive episodes of bipolar disorder
AIM To investigate the efficacy and safety of aripiprazole combined with magnesium valproate in treating depressive episodes of bipolar disorder(BP).METHODS A total of 90 patients with depressive episodes of BP admitted from May 2021 to May 2023 were included in the study and further randomly divided into control group(45 patients,magnesium valproate extended-release tablets)and observation group(45 patients,magnesium valproate extended-release tablets combined with aripiprazole tablets).Treatment outcomes,Hamilton depression rating scale 17(HAMD-17)scores,brain-derived neurotrophic factor,serum inflammatory factors,and adverse reactions between 2 groups of patients were compared.RESULTS The overall clinical effective rate of the observed group(95.56％)was greater than the reference group(62.22％),with a significant difference(P＜0.05).HAMD-17 scores of both groups of patients decreased,and the observation group was lower than the control group after treatment(P＜0.05).Levels of interleukin-4,interleukin-10,brain-derived neurotrophic factor,and transforming growth factor β1 were significantly increased in both groups of patients,and the observation group was higher than the control group.While levels of interleukin-1 and tumor necrosis factor were significantly decreased,and the observation group was better than the control group(P＜0.05).There was no significant difference in the incidence of adverse reactions between 2 groups(P＞0.05).CONCLUSION Aripiprazole combined with magnesium valproate could enhance treatment outcomes for bipolar depression,alleviate depressive symptoms,reduce inflammation,bolster immune function,and modulate nerve growth factor levels,with a good safety profile.The combination regimen is worthy of clinical promotion.
aripiprazolemagnesium valproatedepressive episodes of bipolar disorderefficacysafety
万方数据
维普
